Autoimmunity reviews最新文献

{"title":"A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence","authors":"Maurizio Bruschi ,&nbsp;Andrea Angeletti ,&nbsp;Marco Prunotto ,&nbsp;Pier Luigi Meroni ,&nbsp;Gian Marco Ghiggeri ,&nbsp;for the Zeus consortium,&nbsp;Gabriella Moroni ,&nbsp;Renato Alberto Sinico ,&nbsp;Franco Franceschini ,&nbsp;Micaela Fredi ,&nbsp;Augusto Vaglio ,&nbsp;Andrea Cavalli ,&nbsp;Leonardo Scapozza ,&nbsp;Jigar J. Patel ,&nbsp;John C. Tan ,&nbsp;Ken C. Lo ,&nbsp;Lorenzo Cavagna ,&nbsp;Andrea Petretto ,&nbsp;Federico Pratesi ,&nbsp;Paola Migliorini ,&nbsp;Enrico Verrina","doi":"10.1016/j.autrev.2024.103535","DOIUrl":"10.1016/j.autrev.2024.103535","url":null,"abstract":"<div><p>Deposition of autoantibodies in glomeruli is a key factor in the development of lupus nephritis (LN). For a long time, anti-dsDNA and anti-C1q antibodies were thought to be the main cause of the kidney damage. However, recent studies have shown that the list of autoantibidies that have renal tropism and deposit in the kidney in LN is increasing and the link between anti-dsDNA and renal pathology is weak due to potential confounders. Aspecific bindings of dsDNA with cationic antibodies and of anti-dsDNA with several renal antigens such as actinin, laminin, entactin, and annexinA2 raised doubts about the specific target of these antibodies in the kidney. Moreover, the isotype of anti-dsDNA in SLE and LN has never received adequate interest until the recent observation that IgG2 are preponderant over IgG1, IgG3 and IgG4.</p><p>Based on the above background, recent studies investigated the involvement of anti-dsDNA IgG2 and of other antibodies in LN. It was concluded that circulating anti-dsDNA IgG2 levels do not distinguish between LN versus non-renal SLE, and, in patients with LN, their levels do not change over time. Circulating levels of other antibodies such as anti-ENO1 and anti-H2 IgG2 were, instead, higher in LN vs non-renal SLE at the time of diagnosis and decreased following therapies. Finally, new classes of renal antibodies that potentially modify the anti-inflammatory response in the kidney are emerging as new co-actors in the pathogenetic scenario. They have been defined as ‘second wave antibodies’ for the link with detoxifying mechanisms limiting the oxidative stress in glomeruli that are classically stimulated in a second phase of inflammation.</p><p>These findings have important clinical implications that may modify the laboratory approach to LN. Serum levels of anti-ENO1 and anti-H2 IgG2 should be measured in the follow up of patients for designing the length of therapies and identify those patients who respond to treatments. Anti-SOD2 could help to monitor and potentiate the anti-inflammatory response in the kidney.</p></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 5","pages":"Article 103535"},"PeriodicalIF":13.6,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140326311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redox mechanisms in autoimmune thyroid eye disease","authors":"Francesco Buonfiglio ,&nbsp;Katharina A. Ponto ,&nbsp;Norbert Pfeiffer ,&nbsp;George J. Kahaly ,&nbsp;Adrian Gericke","doi":"10.1016/j.autrev.2024.103534","DOIUrl":"10.1016/j.autrev.2024.103534","url":null,"abstract":"<div><p>Thyroid eye disease (TED) is an autoimmune condition affecting the orbit and the eye with its adnexa, often occurring as an extrathyroidal complication of Graves' disease (GD). Orbital inflammatory infiltration and the stimulation of orbital fibroblasts, triggering de novo adipogenesis, an overproduction of hyaluronan, myofibroblast differentiation, and eventual tissue fibrosis are hallmarks of the disease. Notably, several redox signaling pathways have been shown to intensify inflammation and to promote adipogenesis, myofibroblast differentiation, and fibrogenesis by upregulating potent cytokines, such as interleukin (IL)-1β, IL-6, and transforming growth factor (TGF)-β. While existing treatment options can manage symptoms and potentially halt disease progression, they come with drawbacks such as relapses, side effects, and chronic adverse effects on the optic nerve. Currently, several studies shed light on the pathogenetic contributions of emerging factors within immunological cascades and chronic oxidative stress. This review article provides an overview on the latest advancements in understanding the pathophysiology of TED, with a special focus of the interplay between oxidative stress, immunological mechanisms and environmental factors. Furthermore, cutting-edge therapeutic approaches targeting redox mechanisms will be presented and discussed.</p></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 5","pages":"Article 103534"},"PeriodicalIF":13.6,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1568997224000259/pdfft?md5=f294d9cea0af2aafe7a9385f34094adc&pid=1-s2.0-S1568997224000259-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140288147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus","authors":"Fabio Salvatore Macaluso ,&nbsp;Flavio Caprioli ,&nbsp;Laura Benedan ,&nbsp;Cristina Bezzio ,&nbsp;Roberto Caporali ,&nbsp;Alberto Cauli ,&nbsp;Maria Sole Chimenti ,&nbsp;Francesco Ciccia ,&nbsp;Salvatore D'Angelo ,&nbsp;Massimo Claudio Fantini ,&nbsp;Stefano Festa ,&nbsp;Florenzo Iannone ,&nbsp;Ennio Lubrano ,&nbsp;Paolo Mariani ,&nbsp;Claudio Papi ,&nbsp;Giuseppe Provenzano ,&nbsp;Daniela Pugliese ,&nbsp;Antonio Rispo ,&nbsp;Simone Saibeni ,&nbsp;Carlo Salvarani ,&nbsp;Roberto Gerli","doi":"10.1016/j.autrev.2024.103533","DOIUrl":"10.1016/j.autrev.2024.103533","url":null,"abstract":"<div><p>Spondyloarthritis (SpA) is the most frequent extraintestinal manifestation in patients with inflammatory bowel diseases (IBD). When IBD and spondyloarthritis coexist, musculoskeletal and intestinal disease features should be considered when planning a therapeutic strategy. Treatment options for IBD and SpA have expanded enormously over the last few years, but randomized controlled trials with specific endpoints focused on SpA are not available in the IBD setting. To address this important clinical topic, the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and the Italian Society of Rheumatology (SIR) jointly planned to draw updated therapeutic recommendations for IBD-associated SpA using a pseudo-Delphi method. This document presents the official recommendations of IG-IBD and SIR on the management of IBD-associated SpA in the form of 34 statements and 4 therapeutic algorithms. It is intended to be a reference guide for gastroenterologists and rheumatologists dealing with IBD-associated SpA.</p></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 5","pages":"Article 103533"},"PeriodicalIF":13.6,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1568997224000247/pdfft?md5=95d2779faaa841c02b00711aa22154fa&pid=1-s2.0-S1568997224000247-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140193176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases","authors":"Mirre De Bondt ,&nbsp;Janne Renders ,&nbsp;Sofie Struyf ,&nbsp;Niels Hellings","doi":"10.1016/j.autrev.2024.103532","DOIUrl":"10.1016/j.autrev.2024.103532","url":null,"abstract":"<div><p>Bruton's tyrosine kinase (BTK) is a cytoplasmic, non-receptor signal transducer, initially identified as an essential signaling molecule for B cells, with genetic mutations resulting in a disorder characterized by disturbed B cell and antibody development. Subsequent research revealed the critical role of BTK in the functionality of monocytes, macrophages and neutrophils. Various immune cells, among which B cells and neutrophils, rely on BTK activity for diverse signaling pathways downstream of multiple receptors, which makes this kinase an ideal target to treat hematological malignancies and autoimmune diseases. First-generation BTK inhibitors are already on the market to treat hematological disorders. It has been demonstrated that B cells and myeloid cells play a significant role in the pathogenesis of different autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome. Consequently, second-generation BTK inhibitors are currently being developed to treat these disorders. Despite the acknowledged involvement of BTK in various cell types, the focus on B cells often overshadows its impact on innate immune cells. Among these cell types, neutrophils are often underestimated in the pathogenesis of autoimmune diseases. In this narrative review, the function of BTK in different immune cell subsets is discussed, after which an overview is provided of different upcoming BTK inhibitors tested for treatment of autoimmune diseases. Special attention is paid to BTK inhibition and its effect on neutrophil biology.</p></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 5","pages":"Article 103532"},"PeriodicalIF":13.6,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140193175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence","authors":"Xiaoying Sun ,&nbsp;Ziyang Cui ,&nbsp;Qingyun Wang ,&nbsp;Liu Liu ,&nbsp;Xiaojie Ding ,&nbsp;Jiao Wang ,&nbsp;Xiaoce Cai ,&nbsp;Bin Li ,&nbsp;Xin Li","doi":"10.1016/j.autrev.2024.103530","DOIUrl":"10.1016/j.autrev.2024.103530","url":null,"abstract":"<div><h3>Background</h3><p>Formation of anti-drug antibodies (ADAs) against biologics is an important cause of psoriasis treatment failure.</p></div><div><h3>Objective</h3><p>This study aimed to summarize the characteristics of ADAs formation under different biological therapies and the influence of ADAs on the clinical effects and safety of biologics in patients with psoriasis.</p></div><div><h3>Methods</h3><p>PubMed, Embase, and Web of Science databases were searched from their inception to August 2022. Studies on biologics that assessed ADA levels in patients with psoriasis were included. The Cochrane risk-of-bias tool was used to assess the quality of randomized controlled trials (RCTs), the Newcastle-Ottawa Quality Assessment Scale (NOS) for case-control and cohort studies, and the Joanna Briggs Institute (JBI) critical appraisal checklist for single-arm studies. We calculated the pooled incidence with a random-effects model using R software. Subgroup analyses revealed that differences in patient characteristics, disease conditions, study design, and immunoassays may influence ADA generation and detection.</p></div><div><h3>Results</h3><p>The analysis included 86 studies, with a total population of 42,280 individuals. The pooled ADA rates were 0.49%, 2.20%, 2.38%, 4.08%, 7.38%, 7.94%, 14.29%, 21.93%, 29.70%, 31.76%, and 39.58% for secukinumab, etanercept, brodalumab, ustekinumab, tildrakizumab, guselkumab, ixekizumab, risankizumab, infliximab, adalimumab, and bimekizumab, respectively. &gt;70% (95% CI, 0.71–0.81) of ADAs against adalimumab were neutralizing antibodies, and over 70% of ADAs against secukinumab and brodalumab were transient. Concomitant methotrexate therapy with tumor necrosis factor-α (TNF-α) inhibitors decreased ADA levels. Lower infliximab doses and intermittent therapy with interleukin (IL)-23 p19 inhibitors increased ADA formation. Additionally, ADA formation under treatment using TNF-α inhibitors and IL-12/23 p40 inhibitors was associated with lower response rates or serum drug levels, but only high ADA titers reduced the clinical effects of IL-17 inhibitors. The occurrence of IL-23 p19 and TNF-α inhibitors has been linked to injection-site reactions.</p></div><div><h3>Conclusions</h3><p>Among the 11 biologics, secukinumab, etanercept, and brodalumab resulted in the lowest ADA formation rates. Immunogenicity contributes to lower biological efficacy and a higher likelihood of injection-site reactions. Low doses, intermittent treatment may increase ADA formation. An appropriate biologic should be selected based on the ADA formation rate and course of treatment.</p></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 4","pages":"Article 103530"},"PeriodicalIF":13.6,"publicationDate":"2024-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology, clinical features, risk factors, and outcomes in anti-glomerular basement membrane disease: A systematic review and meta-analysis","authors":"Huang Kuang ,&nbsp;Nan Jiang ,&nbsp;Xiao-Yu Jia ,&nbsp;Zhao Cui ,&nbsp;Ming-Hui Zhao","doi":"10.1016/j.autrev.2024.103531","DOIUrl":"10.1016/j.autrev.2024.103531","url":null,"abstract":"<div><p>Anti-glomerular basement membrane (GBM) disease is a small-vessel vasculitis that represents the most aggressive form of autoimmune glomerulonephritis. The study aimed to investigate the prevalence, clinical characteristics, risk factors, and outcomes of anti-GBM disease through a systematic review and meta-analysis involving 47 studies with 2830 patients. The overall incidence of anti-GBM disease ranged from 0.60 to 1.79 per million population per annum. In rapidly progressive glomerulonephritis and crescentic glomerulonephritis, the pooled incidence rates were 8.0% and 12.8%, respectively. The pooled prevalence rates of anti-GBM antibodies, antineutrophil cytoplasmic antibodies (ANCA), and lung hemorrhage were 88.8%, 27.4%, and 32.6%, respectively. Patients with combined ANCA positivity demonstrated a prognosis comparable to those patients with only anti-GBM antibodies, though with differing clinical features. The pooled one-year patient and kidney survival rates were 76.2% and 30.2%, respectively. Kidney function on diagnosis and normal glomeruli percentage were identified as strong prognostic factors. This study represents the first comprehensive meta-analysis on anti-GBM disease, providing insights into its management. However, caution is warranted in interpreting some results due to the observational nature of the included studies and high heterogeneity.</p></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 4","pages":"Article 103531"},"PeriodicalIF":13.6,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140142656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebral vasculitis as a clinical manifestation of neurosarcoidosis: A scoping review","authors":"Yaroslav Winter ,&nbsp;Sergiu Groppa ,&nbsp;Timo Uphaus ,&nbsp;Erik Ellwardt ,&nbsp;Sven Fuest ,&nbsp;Sven Meuth ,&nbsp;Stefan Bittner ,&nbsp;Eyad Hayani","doi":"10.1016/j.autrev.2024.103528","DOIUrl":"10.1016/j.autrev.2024.103528","url":null,"abstract":"<div><p>The occurrence of cerebral vasculitis in individuals with neurosarcoidosis (NS) is considered to be rare. Although the number of relevant publications has increased in recent years, evidence is mostly limited to case reports. To obtain a better understanding of this rare and severe manifestation of disease, we carried out a scoping review on cerebral vasculitis in patients diagnosed with NS. The results of the review indicate that the diagnosis of cerebral vasculitis in patients with NS is made especially in patients with systemic sarcoidosis. However, recurrent strokes in patients with NS remains the main indicator of cerebral vasculitis. A tissue biopsy is considered the gold standard to confirm the diagnosis despite occasional false-negative results. Glucocorticoids and steroid-sparing agents are the most successful current treatments. Favorable outcomes were observed with strategies targeting TNFα and B cells. The goal of this review is to summarize the current literature and treatment options for cerebral vasculitis in patients with NS.</p></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 4","pages":"Article 103528"},"PeriodicalIF":13.6,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140139792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural cell heterogeneity underlies the differential contribution of IL-17A, IL-17F and IL-23 to joint versus skin chronic inflammation","authors":"Marie Robert,&nbsp;Pierre Miossec","doi":"10.1016/j.autrev.2024.103529","DOIUrl":"10.1016/j.autrev.2024.103529","url":null,"abstract":"<div><p>The current therapeutic strategy used in immune-mediated inflammatory diseases (IMIDs) primarily targets immune cells or associated-pathways. However, recent evidence suggests that the microenvironment modulates immune cell development and responses. During inflammation, structural cells acquire a pathogenetic phenotype and the interactions with immune cells are often greatly modified. Understanding the importance of these tissue-specific interactions may allow to explain why some biologics are effective in some IMIDs but not in others. The differential effects of interleukin (IL)-17 A, IL-17F and IL-23 in joint versus skin inflammation depends on structural cell heterogeneity. In addition, the sometimes opposite effects of immune/structural cell interactions on the production of these cytokines illustrate the importance of these cells in chronic inflammation, using the examples of rheumatoid arthritis, psoriasis and spondyloarthritis. This review describes these concepts, shows their interests through clinical observations, and finally discusses strategies to optimize therapeutic strategies.</p></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 4","pages":"Article 103529"},"PeriodicalIF":13.6,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140139793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical phenotype of AAV, anti-GBM disease and double-positive patients after SARS-CoV-2 vaccination","authors":"Yisha Li ,&nbsp;Jie Wang ,&nbsp;Shuang Liang,&nbsp;Yan Zhang,&nbsp;Zhe Feng,&nbsp;Guangyan Cai","doi":"10.1016/j.autrev.2024.103521","DOIUrl":"10.1016/j.autrev.2024.103521","url":null,"abstract":"<div><p>The number of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), anti-glomerular basement membrane (GBM) disease and double-positive patients (DPPs) following the coronavirus disease 2019 (COVID-19) vaccine reported in the literature is increasing, we reviewed the reported cases of AAV, anti-GBM disease and DPPs subsequent to COVID-19 vaccination, and compared the disparities in DPPs who received the COVID-19 vaccination and those who did not. We did not observe any differences in clinical phenotype of AAV, anti-GBM disease and DPPs before and after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination.</p></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 4","pages":"Article 103521"},"PeriodicalIF":13.6,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140136419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethnicity also influences the clinical heterogeneity of mixed connective tissue disease of childhood onset: The French West Indies experience","authors":"Arthur Felix ,&nbsp;Fabienne Louis-Sidney ,&nbsp;Christophe Deligny ,&nbsp;Benoit Suzon","doi":"10.1016/j.autrev.2024.103519","DOIUrl":"10.1016/j.autrev.2024.103519","url":null,"abstract":"","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 4","pages":"Article 103519"},"PeriodicalIF":13.6,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140048651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}